Interleukin-12-secreting human papillomavirus type 16–transformed cells provide a potent cancer vaccine that generates E7-directed immunity
✍ Scribed by Sophie Hallez; Odile Detremmerie; Christina Giannouli; Kris Thielemans; Thomas F. Gajewski; Arsène Burny; Oberdan Leo
- Book ID
- 101234481
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- French
- Weight
- 177 KB
- Volume
- 81
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
The development of a vaccine that would be capable of preventing or curing the (pre)cancerous lesions induced by genital oncogenic human papillomaviruses (HPVs) is the focus of much research. Many studies are presently evaluating vaccines based on the viral E6 and E7 oncoproteins, both of which are continually expressed by tumor cells. The success of a cancer vaccine relies, in large part, on the induction of a tumor-specific Th1-type immunity. In this study, we have evaluated the ability of B7-related and/or interleukin-12 (IL-12)-expressing, non-immunogenic murine HPV16-transformed BMK-16/myc cells, to achieve this goal. BMK-16/myc cells engineered to express surface B7-1 or B7-2 molecules remain tumorigenic in syngeneic BALB/c mice, suggesting that expression of these molecules alone is not sufficient to induce tumor regression. In contrast, mice injected with tumor cells engineered to secrete IL-12 remained tumorfree, demonstrating that IL-12 expression is sufficient to induce tumor rejection. IL-12-secreting BMK-16/myc cells were further shown to induce potent and specific long-term tumor resistance, even after irradiation. B7-1 was found to slightly but systematically improve anti-tumor immunity elicited by IL-12-secreting BMK-16/myc cells. Injection of irradiated B7-1/IL-12 ϩ BMK-16/myc cells generates longlasting, Th1-type, BMK-16/myc-directed immunity in tumorresistant mice. These mice display a memory-type, E7specific, cell-mediated immune response, which is potentially significant for clinical applications.